A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers.
In a double-blind placebo controlled trial intranasal NPC 567, a bradykinin antagonist, failed to alleviate the symptoms of experimental rhinovirus colds. Indeed, there was evidence that the drug enhanced the symptoms although no irritant effect was detected on the uninfected nasal mucosa.
Higgins
P G
PG
MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
Barrow
G I
GI
Tyrrell
D A
DA
D000328:Adult; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D003139:Common Cold / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010850:Picornaviridae Infections / Q000188:drug therapy*; D012229:Rhinovirus
C053010:NPC 567; D001920:Bradykinin